Compare Innoviva, Inc. (INVA) vs Regeneron Pharmaceuticals, Inc. (REGN) Stock

Innoviva, Inc. (INVA) offers the better valuation at 6.7x trailing P/E (11.3x forward), making it the more compelling value choice. Analysts rate Innoviva, Inc. (INVA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc. (INVA) is the cheapest at 6.7x versus Regeneron Pharmaceuticals, Inc. at 18.8x. On forward P/E, Innoviva, Inc. is actually cheaper at 11.3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Innoviva, Inc. wins at 1.10x versus Regeneron Pharmaceuticals, Inc.'s 2.72x — a reasonable growth-adjusted valuation.

Over the past 5 years, Innoviva, Inc. (INVA) delivered a total return of +101.2%, compared to +74.7% for Regeneron Pharmaceuticals, Inc. (REGN). A $10,000 investment in INVA five years ago would be worth approximately $20K today (assuming dividends reinvested). Over 10 years, the gap is even starker: REGN returned +94.4% versus INVA's +85.1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc. (INVA) is the lower-risk stock at 0.07β versus Regeneron Pharmaceuticals, Inc.'s 0.58β — meaning REGN is approximately 719% more volatile than INVA relative to the S&P 500.

Innoviva, Inc. (INVA) is the more profitable company, earning 63.8% net margin versus 31.4% for Regeneron Pharmaceuticals, Inc. — meaning it keeps 63.8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38.5% versus 25.7% for REGN. At the gross margin level — before operating expenses — REGN leads at 86.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential. By this metric, Innoviva, Inc. (INVA) is the more undervalued stock at a PEG of 1.10x versus Regeneron Pharmaceuticals, Inc.'s 2.72x. A PEG below 1.5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Innoviva, Inc. (INVA) trades at 11.3x forward P/E versus 17.2x for Regeneron Pharmaceuticals, Inc. — 5.9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INVA: 46.1% to $32.50.

In this comparison, REGN (0.4% yield) pays a dividend. INVA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Innoviva, Inc. (INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.07)). Both have compounded well over 10 years (INVA: +85.1%, REGN: +94.4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: INVA is a small-cap deep-value stock; REGN is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.